Amlodipine induced chylous ascites in a patient undergoing peritoneal dialysis: A case report

  • Sakul Gupta Acharya Shri Chander College of Medical Sciences and Hospital
  • Mega Lahori Department of Pathology, Acharya Shri Chander College of Medical Sciences and Hospital
  • Sanjay Bhat Acharya Shri Chander College of Medical Sciences and Hospital
Keywords: Amlodipine, Chylous Ascites, Peritoneal dialysis

Abstract

Amlodipine besilate, long-acting dihydropyridine type calcium channel blocker is widely used as an antihypertensive agent. In some reports, long-acting dihydropyridine type calcium channel blockers caused chylous ascites in peritoneal dialysis patients but none of the cases was associated with use of amlodipine. Here, we describe a case of a patient who was on peritoneal dialysis for CKD and developed chylous ascites after he was prescribed amlodipine for hypertension. The chylous ascites resolved after cessation of amlodipine therapy. The exact mechanism of this phenomenon is still not established although few speculative theories are known. A thorough clinical, laboratory and imaging assessment of this patient didn’t suggest any alternative diagnosis. We conclude that this patient’s chylous ascites was amlodipine related and physicians should be aware of the possibility of ascites due to the administration of long-acting dihydropyridine type calcium channel blockers particularly in those undergoing peritoneal dialysis.

Author Biographies

Sakul Gupta, Acharya Shri Chander College of Medical Sciences and Hospital
Department of Internal MedicineAssistant Professor, 
Mega Lahori, Department of Pathology, Acharya Shri Chander College of Medical Sciences and Hospital
Department of Pathology,Postgraduate student
Sanjay Bhat, Acharya Shri Chander College of Medical Sciences and Hospital
Department of Internal Medicine,Assistant Professor

References

1. Laterre PF, Dugernier T, Reyneart MS. Chylous Ascites: diagnosis, causes and management. Acta Gastroenterol Belg, 2000, July-Sept, 63(3): 260-63.
2. Said A. Al-Busafi, Ghali P, Deschênes M and Wong P. “Chylous Ascites: Evaluation and Management,” ISRN Hepatology- 2014, Article ID 240473, 10 pages, 2014. doi:10.1155/2014/240473
3. Tsao YT, Chen WL. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2009; 75: 868.
4. Graice R, Bargman JM. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2010; 77:165.
5. Yoshimoto K, Saima S, Nakamura Y, Nakayama M, Kubo H, Kawaguchi Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol, 1998; 50: 90–93.
6. Yoshimoto K, Saima S, Echizen H, Nakamura Y, Ishizaki T. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1993; 40:114–17
7. Teitelbaum I. Cloudy peritoneal dialysate: it’s not always infection. Peritoneal Dialysis: A Clinical Update. Volume 150. Basel, Switzerland: Karger AG; 2006: 187–94.
8. Yang WS, Huang JW, Chen HW, Tsai TJ, Wu KD. Lercanid¬ipine-induced chylo-peritoneum in patients on peritoneal dialysis. Perit Dial Int, 2008; 28: 632–36.
Published
2016-08-18
Section
Case Reports